A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Rimouski, Boston MA, New Haven CT, Quebec,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase3, Recruiting
Active & Responsive
TReating Incontinence for Underlying Mental and Physical Health
for
Urinary Incontinence, Urge, Urinary Incontinence,
Location: Palo Alto CA, San Francisco CA
Sponsor: University of California, San Francisco
Sex: Female
Age: 60+
Code: NCT05362292
Recruiting
Active & Responsive
Daily Upgrade Trial
for
Healthy Women
Location: Chapel Hill NC
Sponsor: University of North Carolina, Chapel Hill
Sex: Female
Age: 25 - 45
Code: NCT07792603
Recruiting
Active & Responsive
Evaluation of Filler Injection for Chin Profile Enhancement